HemoTech Findings Show Significant Promise For Combating Two Major Complications Involved In Treating Patients With Coronary Artery Disease

Company To Present Findings Of Recent Study At Two Premier International Biotechnology Conferences

DALLAS--()--HemoBioTech, Inc. (OTCBB: HMBT), a biopharmaceutical company focused on developing the first commercial substitute for human blood, has gathered results from a pre-clinical study of its HemoTech blood substitute product in patients undergoing percutaneous coronary intervention (PCI) through angioplasty and stent implantation, the most common PCI procedures. HemoBioTech scientists are scheduled to present the studys findings at two international industry conferences later this month.

In the recent ex vivo human study, HemoTech showed markedly reduced platelet aggregation, one of the major complications associated with PCI procedures. HemoTech also demonstrated the potential for preventing restenosis (narrowing of the artery), another potentially dangerous side effect of PCI. The results of the preclinical study will be presented by scientists from HemoBioTech and Texas Tech University Health Sciences Center at the following two conferences: the XIth International Symposium on Blood Substitutes (ISBS) in Beijing, China (October 19-22, 2007) and the combined 45th Annual Meeting of the Japanese Society for Artificial Organs (JSAO) and 2nd Congress of the International Federation for Artificial Organs (IFAO) in Osaka, Japan (October 28-31, 2007).

PCI, with balloon dilatation or stent implantation, has revolutionized the treatment of coronary artery disease. However, two major complications inherent to this procedure have become evident: thrombosis and restenosis. More than one million PCI procedures are performed annually in the United States at a cost of more than $30 billion.

According to the American Heart Association, coronary artery disease is the leading cause of mortality in the U.S. and was responsible for more than one of every five American deaths in 2001. Coronary artery disease is caused by the buildup of plaque on the inside of the coronary arteries, the blood vessels that supply oxygen-rich blood to the heart muscle. Plaque is made up of excess cholesterol, calcium, and other substances that circulate in blood and, over time, build up inside artery walls.

As we make progress towards initiating clinical trials in India, we are excited to learn of the added benefits our product could potentially extend to the medical community, said Arthur Bollon, Ph.D., Chairman and CEO of HemoBioTech. These findings help to strengthen an already solid belief in HemoTech and the value it could present to the market if approved. It is an honor to present our findings at these highly reputable conferences.

About HemoBioTech, Inc.

HemoBioTech is working on the development and commercialization of HemoTech, a novel human blood substitute technology exclusively licensed from Texas Tech University Health Sciences Center. HemoTech is composed of bovine hemoglobin that is chemically modified with adenosine triphosphate, adenosine, and glutathione. In addition to carrying oxygen through the bloodstream, HemoTech also induces erythropoiesis (red blood cell production). Based on preclinical studies and an initial foreign human clinical study, the company believes that HemoTech, due to its novel chemical composition, may significantly diminish or even eliminate the intrinsic toxicities that have plagued other attempts at developing blood substitutes. HemoTech is currently undergoing additional studies to confirm and possibly expand on these results. HemoTech is being developed to help reduce or eliminate the danger resulting from acute blood loss in trauma, surgery, and other conditions. Corporate headquarters are located at 5001 Spring Valley Road, Suite 1040-West, Dallas, Texas 75244. For further information visit our website at http://www.hemobiotech.com.

Safe Harbor Statement

Except for historical information, the matters discussed in this news release may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief, or current expectations of HemoBioTech and its management and are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a difference include, among others the successful pre-clinical development, the successful completion of clinical trials, the FDA review process and other governmental regulation, pharmaceutical collaborator interest and ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement, and other factors which are included in HemoBioTechs Annual Report on Form 10-KSB for the year ended December 31, 2006, as amended, and HemoBioTechs other reports filed with the Securities and Exchange Commission.

Contacts

HemoBioTech, Inc.
Arthur P. Bollon, Ph.D., 972-455-8950
Chief Executive Officer
abollon@hemobiotech.com
www.hemobiotech.com
or
Investor Relations:
The Investor Relations Group, Inc.
Christine Berni/Joseph Triunfo, 212-825-3210
cberni@investorrelationsgroup.com
jtriunfo@investorrelationsgroup.com
or
Media:
Janet Vasquez/Michaela Heller, 212-825-3210
jvasquez@investorrelationsgroup.com
mheller@investorrelationsgroup.com

Contacts

HemoBioTech, Inc.
Arthur P. Bollon, Ph.D., 972-455-8950
Chief Executive Officer
abollon@hemobiotech.com
www.hemobiotech.com
or
Investor Relations:
The Investor Relations Group, Inc.
Christine Berni/Joseph Triunfo, 212-825-3210
cberni@investorrelationsgroup.com
jtriunfo@investorrelationsgroup.com
or
Media:
Janet Vasquez/Michaela Heller, 212-825-3210
jvasquez@investorrelationsgroup.com
mheller@investorrelationsgroup.com